
Revolutionizing Eye Care: The Race to Cure Age-Related Blindness Takes a Bold Step Forward
Character Biosciences has secured $93 million in Series B funding to transform the treatment of degenerative eye diseases, particularly age-related macular degeneration (AMD). AMD affects 1 in 8 individuals over 50 and is a leading cause of blindness among older adults globally.